Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

 
• By Sukaina Virji
  
Inchworms
Does Roche's failure indicate need for route change for IO in bladder cancer? • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip